Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Target Cut by JPMorgan Chase & Co.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) had its price objective decreased by research analysts at JPMorgan Chase & Co. from $10.00 to $7.00 in a report issued on Monday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 157.35% from the stock’s previous close.

Several other research firms have also recently commented on RXRX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Thursday, October 15th. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Monday, October 19th. Wall Street Zen raised Recursion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Finally, Morgan Stanley set a $5.90 price objective on Recursion Pharmaceuticals in a research report on Friday, October 16th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $7.58.

Get Our Latest Stock Analysis on Recursion Pharmaceuticals

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX opened at $2.72 on Monday. The firm’s 50-day moving average is $3.75 and its 200-day moving average is $3.47. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -3.02 and a beta of 1.15. Recursion Pharmaceuticals has a 52-week low of $2.50 and a 52-week high of $5.24.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last released its earnings results on Monday, November 2nd. The company reported ($0.22) earnings per share for the quarter, meeting the consensus estimate of ($0.22). Recursion Pharmaceuticals had a negative net margin of 697.15% and a negative return on equity of 47.85%. The business had revenue of $18.55 million during the quarter, compared to analysts’ expectations of $14.81 million. During the same quarter last year, the company earned ($0.36) earnings per share. Equities analysts predict that Recursion Pharmaceuticals will post -0.89 EPS for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 50,000 shares of the company’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $4.84, for a total value of $242,000.00. Following the sale, the director owned 6,108,287 shares of the company’s stock, valued at approximately $29,564,109.08. This represents a 0.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 22,408 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total transaction of $78,876.16. Following the completion of the sale, the chief executive officer directly owned 2,072,890 shares in the company, valued at approximately $7,296,572.80. The trade was a 1.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 167,408 shares of company stock valued at $701,276. 6.65% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC bought a new position in Recursion Pharmaceuticals in the 1st quarter valued at $7,370,000. Bank of New York Mellon Corp boosted its stake in Recursion Pharmaceuticals by 29.3% in the first quarter. Bank of New York Mellon Corp now owns 1,462,631 shares of the company’s stock worth $4,490,000 after purchasing an additional 331,048 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Recursion Pharmaceuticals by 18.2% during the first quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock worth $7,665,000 after purchasing an additional 384,486 shares during the last quarter. First Trust Advisors LP grew its holdings in shares of Recursion Pharmaceuticals by 15.2% during the first quarter. First Trust Advisors LP now owns 2,610,726 shares of the company’s stock worth $8,015,000 after purchasing an additional 344,035 shares during the last quarter. Finally, California State Teachers Retirement System grew its holdings in shares of Recursion Pharmaceuticals by 64.0% during the first quarter. California State Teachers Retirement System now owns 574,637 shares of the company’s stock worth $1,764,000 after purchasing an additional 224,332 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

(Get Free Report)

Recursion Pharmaceuticals, Inc. is a biotechnology company that uses automation, large-scale biological and chemical data, and machine learning to discover and develop medicines. Its platform, known as Recursion OS, is designed to identify relationships between biological processes and potential treatments. The company develops drug candidates for areas including rare diseases and oncology, and it also works with pharmaceutical partners on drug discovery and development. Its research combines laboratory experiments with computational analysis to evaluate potential therapeutic targets and compounds.

Recommended Stories

Analyst Recommendations for Recursion Pharmaceuticals (NASDAQ:RXRX)

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.